# NAD+ Research: Mechanism, Precursor Trials, and What the Data Show | NAD+ > NAD+ research digest: the redox and signaling mechanism, the NMN and NR human trials, side effects, and the open questions — every quantitative claim cited. From the redox cycle and the salvage pathway to the controlled human trials — the NAD+ evidence, logged study by study. ## The short version This page reads the **NAD+** evidence from the bottom up. First the biology: NAD+ (the cell's energy-handling helper molecule) carries electrons to make ATP and is burned by repair enzymes. Then the human trials: oral precursors (NMN, NR) reliably raise blood NAD+, and a few show modest functional signals. Then the honest limits: most dramatic anti-aging results are in mice, IV NAD+ has the weakest evidence, and a 2025 review found human benefit on hard endpoints still unproven. Every number here points to a specific cited study. No claim of treatment, cure, or prevention is made — only what each study measured. ## Mechanism: redox carrier and consumed signaling substrate NAD+ does two jobs at once. As a redox carrier, it cycles between NAD+ (oxidized) and NADH (reduced), accepting electrons in glycolysis and the TCA cycle and donating them to the mitochondrial electron transport chain to drive ATP synthesis [5]. As a signaling substrate, it is *consumed* — not merely borrowed — by three enzyme families: sirtuins (SIRT1-7, NAD+-dependent deacylases that regulate metabolism and stress resistance), PARPs (chiefly PARP1, the DNA-damage response), and CD38/CD157 (NAD glycohydrolases) [5]. Because those enzymes spend NAD+, the cell continuously rebuilds it. The salvage pathway dominates: nicotinamide is converted to NMN by NAMPT — the rate-limiting step — then to NAD+ by NMNAT [5][14]. NAMPT's central, rate-limiting role makes it a recurring target in aging and neurodegeneration biology [14]. This consume-and-rebuild cycle is why a steadily rising NAD-consumer like CD38 can drain tissue NAD+ over a lifetime [2]. ## NAD+ as a dietary supplement: what the precursor evidence shows NAD+ is not an FDA-approved drug; it is sold as a dietary supplement, and most oral products are precursors because NAD+ itself is poorly absorbed intact [5]. As a NAD supplement, the precursors have the strongest controlled evidence for one specific thing: raising blood NAD+. Nicotinamide riboside (NR) raised whole-blood NAD+ by 22%, 51%, and 142% at 100, 300, and 1000 mg/day over eight weeks [4]. Oral NMN at 300-900 mg/day raised blood NAD+ dose-dependently over 60 days in a multicenter RCT [3]. Functional endpoints are more mixed. NMN at 250 mg/day for 10 weeks improved muscle insulin sensitivity in prediabetic women without changing body composition or HbA1c [1]. The multicenter NMN trial reported improved walking distance and quality-of-life scores [3]. But a 2025 narrative review concluded that human trials of NAD+ precursors in aging have shown limited efficacy on hard endpoints and that tissue-specific NAD+ data remain sparse [15]. The signal that is solid is the blood-NAD+ rise; the clinical payoff is the unproven part. ## Nicotinamide riboside (NR), the most-studied oral precursor Nicotinamide riboside (NR) carries the deepest controlled dataset of any oral NAD+ precursor. The pivotal dose-response trial in healthy overweight adults established a clean, maintained 22%/51%/142% whole-blood NAD+ increase at 100/300/1000 mg/day over eight weeks, with no flushing and no significant adverse-event difference from placebo, and no rise in LDL cholesterol [4]. NR enters NAD+ synthesis by a distinct route — phosphorylation to NMN by nicotinamide riboside kinases (NRK1/NRK2), whose structural basis is known from human Nrk1 crystal structures [13]. The [nicotinamide riboside trials](/research) make NR the reference point for what oral precursor dosing can reliably achieve at the blood level. ## Nicotinamide mononucleotide (NMN) and its unsettled supplement status Nicotinamide mononucleotide (NMN) is a direct NAD+ precursor, one biochemical step from NAD+. Human trials support it: 250 mg/day improved muscle insulin sensitivity over 10 weeks [1], and 300-900 mg/day raised blood NAD+ dose-dependently over 60 days [3]. Its regulatory status, however, is contested. The FDA has taken the position that NMN is excluded from the dietary-supplement definition because it was authorized for investigation as a drug — a marketplace dispute that has created commercial uncertainty, not a finding that NMN is unsafe or banned [15]. This digest presents that status as filed: an unsettled regulatory question, reported plainly. ## Mitochondrial function depends on the NAD+ salvage system Several studies tie NAD+ salvage directly to mitochondrial energy output. In mouse C2C12 myoblasts and intact skeletal muscle, knocking down NAMPT lowered NAD+ and impaired maximal respiratory and oxidative-phosphorylation capacity — and supplying nicotinamide riboside restored NAD+ and raised maximal respiratory capacity [11]. In aged mice, CD38 deletion preserved NAD+ and SIRT3 activity and protected mitochondrial function [2]. The throughline: when the salvage system falters, mitochondrial bioenergetics suffer, which is the proposed mechanistic bridge from low NAD+ to the metabolic decline seen in aging tissue [5][12]. ## Beyond metabolism: a neuroinflammation signal in mice NAD+ biology extends past energy metabolism into immune signaling. In APP/PS1 transgenic Alzheimer's-model mice, five months of NAD+ repletion via nicotinamide riboside raised brain NAD+, reduced proinflammatory cytokines, decreased microglial and astrocyte activation, lowered NLRP3 inflammasome expression, and improved cognitive and synaptic function — with the mechanism running through normalization of the cGAS-STING innate-immune pathway [8]. This is a mouse model, and the result describes neuroinflammation and behavior in that model; it is not evidence that NAD+ treats, reverses, or prevents Alzheimer's disease in people. It is reported here as a mechanistic finding, not a clinical claim. ## Tolerability and safety signals in the studies Oral precursor trials report few adverse events. NR at 100-1000 mg/day produced no flushing and no significant adverse-event difference from placebo over eight weeks [4], and was tested up to 3000 mg/day in a separate Parkinson's-disease safety study. Oral NMN at 250-900 mg/day reported no safety issues across its trials [1][3]. The route that draws caution is injectable: infused NAD+ can cause chest and abdominal discomfort, flushing, and nausea if delivered too fast, and a compounded injectable NAD+ product was subject to an FDA Class I recall for elevated bacterial endotoxin. A further context-dependent caution noted in the literature is that NAD+ supports proliferating cells, so its role in cancer is dual and not uniformly benign. These are study observations and documented concerns, not medical advice. --- An arcade-console reading of the NAD+ literature — the coenzyme logged apart from its precursors NMN and NR, the blood-NAD+ the trials actually moved scored against the gaps the rodent and IV data leave open; no clinic behind the console, nothing here infused, ordered, or sold.